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Autism spectrum disorders (ASDs) are increasing in incidence but have an incompletely understood etiology. Tools
for uncovering clues to the cause of ASDs and means for diagnoses are valuable to the field. Mass Spectrometry
(MS) has been a useful method for evaluating differences between individuals with ASDs versus matched controls.
Different biological substances can be evaluated using MS, including urine, blood, saliva, and hair. This technique
has been used to evaluate relatively unsupported hypotheses based on introduction of exogenous factors, such
as opiate and heavy metal excretion theories of ASDs. MS has also been used to support disturbances in
serotonin-related molecules, which have been more consistently observed in ASDs. Serotonergic system markers,
markers for oxidative stress, cholesterol system disturbances, peptide hypo-phosphorylation and methylation have
been measured using MS in ASDs, although further analyses with larger numbers of subjects are needed (as well as
consideration of behavioral data). Refinements in MS and data analysis are ongoing, allowing for the possibility that
future studies examining body fluids and specimens from ASD subjects could continue to yield novel insights.
This review summarizes MS investigations that have been conducted to study ASD to date and provides insight
into future promising applications for this technique, with focus on proteomic studies.
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Introduction
Mass spectrometry (MS) has been employed as a tool for
understanding various biomedical disorders, and is more re-
cently being used to investigate psychiatric disorders, includ-
ing autism spectrum disorders (ASDs). Although initial MS
studies have focused on identifying exogenous factors, more
recent investigations are being conducted to understand en-
dogenous protein changes and to identify possible ASD bio-
markers. Here we summarize how MS has been employed
to understand ASDs, and we provide a perspective on the
likely future of investigations of ASDs using this technique.
Autism spectrum disorders (ASDs) are characterized
by social deficits, repetitive/stereotypical behaviors and
interests, as well as communication problems [1]. These
disorders include autism, Asperger’s syndrome and per-
vasive developmental disorder not otherwise specified* Correspondence: awoods@clarkson.edu
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reproduction in any medium, provided the or(PDD-NOS) [2]. Most recent available estimates of ASD
indicate a prevalence of 1 in 88 US children. ASDs are
more frequent in boys than girls, with a relative preva-
lence of one in 54 boys and one in 252 girls [3]. This in-
dicates a continued increase in ASD incidence, however,
the contribution of a true increase versus improvements
in awareness and diagnosis is currently unknown [3].
Many researchers believe that improved detection alone
does not account for the increased ASD incidence [4].
Current classifications for ASDs may change in the
upcoming DSM-V (Diagnostic and Statistical Manual of
Mental Disorders, fifth edition), in which autism will no
longer be a separate diagnostic category within the larger
classification of Pervasive Developmental Disorder, but
rather encompassed under the broader ASD category.
ASD will also encompass several syndromes that were
individually classified in the DSM-IV-TR (DSM, fourth
edition, Text Revision); Asperger's disorder and PDD-
NOS will be eliminated [5]. Reflecting the common char-
acteristics of ASD subtypes, diagnosis of ASD in DSM-V
will require both “social/communication deficits” and “fix-
ated interests and repetitive behaviors” to be satisfied [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fewer individuals will be diagnosed with ASD [6]. This un-
derscores the need for diagnostic means other than by
simply measuring ASD symptoms.
It has been suggested that a small percentage of chil-
dren diagnosed with ASD will spontaneously completely
recover from symptoms, somewhere between 5-32% de-
pending on the report [7]. However, these assessments
are somewhat contradicted by the fact that ASDs are
pervasive developmental disorders and therefore the
diagnosis cannot be made if the symptoms are transient
in nature. The existence of spontenous recovery remains
an area of controversy. Behavioral interventions for
ASDs, particularly when initiated at as early an age as
possible, have been demonstrated to reduce ASD symp-
toms in 47-48% of cases [8-10]. Improvements in treat-
ment are therefore still greatly needed. Despite the
success of behavioral treatments, they are often initiated
late due to delays in diagnosis. Pharmacological treatments
of approved medications have not yet been demonstrated
to be effective for ASD symptoms [11-13]. Several mGluR5
antagonist candidates as well as GABAergic agonists are
currently being investigated for fragile X syndrome, the
most validated and extensively studied genetic cause of
ASDs [14]. These compounds may represent the first in-
dicated medications for a known syndrome associated
with ASD symptoms. There is no current medication indi-
cated for ASD treatment, although individuals with ASDs
are sometimes prescribed medication for various behav-
ioral symptoms. They also may receive psychiatric medi-
cation for psychiatric comorbidities, such as depression.
ASDs often are accompanied by other psychiatric prob-
lems [15,16].
Current theories of ASD etiology point toward a gen-
etic and environmental interaction [17]. A large body of
evidence on genetic information in ASDs currently ex-
ists [18-21], although this has not made the etiology of
the disorder any less equivocal. Based on a twin study,
risk for ASD is more than 20-times increased in first-
degree relatives [22]. Other studies have reported from
60% to 92% ASD concordance in monozygotic twins and
from 0% to 10% in dizygotic twins [22,23]. Despite this
evidence for a strong genetic component, conclusively
associated genes have remained unidentified, with over
100 genes and 40 genomic loci reported as being associ-
ated with ASD [24,25]. A recent study of de novo muta-
tions in ASD indicates that many mutations found in
individuals with ASDs are in fact unassociated with the
disorder [26]. This evidence points toward possible het-
erogeneity of ASD genetic causality [27] and also indi-
cates that genetic information may not be sufficient to
understand ASD etiology. Multiple genes in conjunction
with environmental factors may interact to cause ASD
[27-29]. The complexity of ASD makes genetic testingfor ASDs relatively unsuccessful in many instances [28].
Although numerous studies have pointed to various bio-
logical disturbances present in children with ASDs [30-33],
no current biological marker is available to aid in ASD
diagnosis. ASDs are diagnosed based on behavioral symp-
toms, including language delays. ASDs therefore often go
unrecognized until a child is at least 2 years old or even
older, and current screening instruments for ASDs gener-
ate many false positives [34].
In this regard, we advocate the use of the mass spec-
trometer as a possible screening instrument for ASDs
for many reasons. High-performing mass spectrometers,
simplified analytical workflows and versatile data analysis
tools render the technique easy, fast, accurate, reprodu-
cible and reliable compared to genetic studies. Further,
dynamics at the environmental, developmental and gen-
etic stages are truly reflected at the protein level. More-
over, proteomics could lead to the discovery of proteome
fingerprints or profiles specific to ASD and therefore to
biomarker discovery for the diagnosis, prognosis, monitor-
ing and target identification for treatments for this dis-
order (Figure 1).
Mass spectrometry and proteomic analysis in autism
spectrum disorders
Proteomics has the power to complement genetic infor-
mation by identifying subtypes of ASD, or by identifying
common protein dysregulations caused by different
genes [35]. Proteomics is the study of the total comple-
ment of proteins at the time of harvest in a specific cell,
organelle, extracellular fluid or tissue [36]. Proteomics
can convey information that goes beyond genomic analysis,
such as indications of active protein levels [37] or possible
important post-translational modifications such as glyco-
sylation, phosphorylation, and formation/destruction of
disulfide bridges that maintain or disturb the protein’s
three-dimensionality [35], summarized in Figure 2. The
mass spectrometer is the workhorse of proteomic analyses
but it can also be used to identify other relevant com-
pounds [38] potentially associated with ASDs, such as
environmental or ingested toxins or metabolites [39].
Several different bodily fluids or products can be ana-
lyzed by MS: urine, blood sera, saliva, hair and tissue bi-
opsies (Figure 3). Proteomic analysis of brain tissue,
including synaptic proteins, using MS is also possible, al-
though this approach tends to be limited to ASD animal
models [40,41]. There are different reasons why a spe-
cific bodily fluid or specimen is chosen for a particular
proteomic experiment. Blood serum contains proteins,
nucleic acids, lipids, and other metabolic products due
to the nature of blood as a complex liquid tissue. This
makes blood serum a rich source of disease biomarkers
[42]. In contrast to blood, urine can be obtained non-



















Figure 1 Current proteomic approaches for MS investigations in ASD. Several studies have suggested the causality of ASD to be of genetic
and/or epigenetic origin as well as to involve exogenous toxicants (metals, environmental contaminants. MS studies have therefore initially
focused on identification of exogenous substances. The proteome, which constitutes the most dynamic entity in human physiology, has not
been as extensively studied. Mass spectrometry can also be used for the analysis of the proteome of ASD samples. This includes modifications of
DNA, such as methylation or histone modification, qualitative proteomics, which identify protein patterns in controls versus ASD without
necessarily implicating specific proteins and ASD proteome identification. This last area of study may be particularly promising for shedding light
on ASD etiology or providing potential diagnostic biomarkers.
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from the kidney and urinary tract. The lower complexity
of the urinary proteome compared to the serum prote-
ome makes detection of low-abundant molecules much
easier. Saliva is comparable to urine with the added
benefit that it contains less salt than urine. Salts are not
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of a protein or a set of proteins (e.g. truncation, phosphorylation, glycosylaMS analysis of proteins or peptides mixtures allows
the identification of proteins by measuring the mass-to-
charge ratio of gas phase ions. A mass spectrometer is
made of three main parts: an ion source, an analyzer,
and a detector. The ion source is the part of the mass
spectrometer where molecules are converted into gas
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Identification, quantitation, PTMs by LC-ESI-MS/MS
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Figure 3 Both MALDI-MS and LC-ESI-MS/MS can be considered for the study of the proteome of ASD samples. MALDI-MS is more
suitable for profiling studies, whereas LC-ESI-MS/MS allows for an in-depth data analysis for protein identification and quantitation as well as for
the search of post-translational modifications.
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mon ion sources are MALDI (Matrix-Assisted Laser De-
sorption/Ionization) and ESI (ElectroSpray Ionization).
Ionization in a MALDI source occurs through a pulsed
laser beam that sublimates molecules whereas in ESI,
ionization takes place by subjecting liquid droplets to
high voltage at atmospheric pressure [44]. There are sev-
eral mass analyzers: TOF (Time-Of-Flight), quadrupole,
ion trap, and FT-ICR (Fourier Transform Ion Cyclotron
Resonance) [45]. There are variants of MS, in which the
intact proteins are analyzed (top-down proteomics), or the
protein molecules are first digested (e.g. by Trypsin) and
the resulting peptides are then analyzed by MS (bottom-up
proteomics) [36,46-60]. Of the two approaches, bottom-up
proteomics is the most established because of some of
the limitations of the top-down approach; it is restricted
to simple protein mixtures, instruments are very expen-
sive and there are difficulties in analyzing high molecular
weight proteins, the presence of post-translational modifi-
cations within the proteins, as well as the presence of both
intact and truncated proteins within the same sample [61].When the peptides generated in bottom-up approaches
are first separated by liquid chromatography (LC) prior to
MS, this approach is termed shotgun proteomics. The sig-
nal obtained from an MS experiment is given in the form
of spectra, which are then compared to a database for pro-
tein identification. We will review and summarize the
results obtained with different analyses of biological mate-
rials for the understanding of changes that occur in ASD
versus controls.
Urinary analysis in ASDs
Of the human biomaterials, urine has been most fre-
quently studied in ASD research. For example, Cass et al.,
(2008) used high pressure liquid chromatography (HPLC)
and Matrix-Assisted Laser Desorption/Ionization-Time-
Of-Flight Mass Spectrometry (MALDI-TOF MS) to ana-
lyze the urine of 65 boys with autism, compared to the
urine of 158 male controls of approximately the same age.
MALDI-TOF MS is the best MS method for determining
peptide or protein mass and for identifying a protein from
a peptide mixture [62]. The purpose of this study was to
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tides are found in the urine of children with autism, which
has been one prevalent view of autism causality, albeit
with little empirical support [63]. Indeed, using MALDI-
TOF MS and HPLC, these investigators found no signifi-
cant differences between the urinary profiles of children
with autism versus controls, including an absence of dif-
ferences in urinary opioid peptides [64]. In another study
by Hunter et al., (2003), the same hypothesis was tested
using LC-UV-MS (Liquid Chromatography-Ultraviolet-MS)
and again the authors could not confirm previous findings
that autism results from an opioid peptide excess [65].
A separate study examining the possible presence of opi-
oids in subjects with ASDs used a highly sensitive Liquid
Chromotography-ElectroSpray Ionization-tandem Mass
Spectrometry (termed LC-ESI-MS/MS or LC-MS/MS for
short). This approach allows a researcher to not only iden-
tify a protein, but also to determine the protein sequence
[62]. MS/MS mode refers to a process by which the mass
spectrometer records the peptides’ spectra (MS mode)
and then peaks are selected according to predefined cri-
teria (e.g. charge state, intensity) for fragmentation via
collision-induced dissociation (CID) to produce product
ions (MS/MS mode). Thus, this mode makes it also pos-
sible to select target peaks or peaks of interest for sequen-
cing or quantitation (single reaction monitoring, SRM)
[62]. The researchers developed this method to be select-
ive for opioid peptides in the urine of 54 children with
ASD versus 15 age-matched controls using a method
called solid-phase extraction (SPE). The targeted peptides
included gliadinomorphin, beta-casomorphin, deltorphin 1,
and deltorphin 2. These investigators also found no evi-
dence for the presence of excessive opioid peptides in the
urine of children with ASDs relative to controls [4]. Based
on these results and the previously mentioned studies, con-
tinued investigation of the opioid hypothesis does not seem
to be warranted and clinical recommendations based on
the opioid hypothesis would appear to be unfounded in
scientific evidence.
Inductively Coupled Plasma-Mass Spectrometry (ICP-
MS) was used to test a different relatively unsupported
theory of autism—that children with autism excrete an
excess of heavy metals [66,67] and that metal chelators
can serve as a treatment for autism. ICP-MS is appropri-
ate for analyzing the elemental composition of materials
and is therefore good for analyzing metals [68]. Unfortu-
nately, this study tested few subjects; 15 children with
autism and 4 controls completed the study. Arsenic,
cadmium, lead and mercury urine content was tested
during a “provoked excretion” versus baseline. Only
three children excreted more metal than baseline during
the provoked excretion; two near the level of detection.
A third child excreted mercury, but this was corrected
based on a dietary change. Overall, this study did notsupport a heavy metal toxicity theory of autism [69].
This is in contrast to a study examining the heavy metal
content of hair. Kern and colleagues examined the pres-
ence of sulfhydryl-reactive metals (mercury, lead, arsenic,
and cadmium) in the hair of 45 children with autism (1–6
yrs of age) versus 45 gender-, age-, and race-matched
typical children. Arsenic, cadmium, and lead were signifi-
cantly lower in the hair of children with autism as com-
pared to matched controls. Mercury was also lower in the
hair of children with autism, but not significantly [39].
The authors concluded that their results could indicate
that children with autism have more difficulty in excreting
toxic metals versus matched typical children [39]. The de-
tection of heavy metals being low in the hair of children
with ASD is an interesting finding however, this theory
does not seem to be consistently supported by other stud-
ies examining the same heavy-metal excretion theory.
In addition to the measurement of exogenously-
introduced factors, urinary analysis of endogenous fac-
tors, such as metabolites, is possible using MS. A study
utilizing LC-MS/MS to analyze the urine of young adults
with severe ASD and schizophrenia versus healthy con-
trols (n=15, 18 and 18, respectively) found that butofenine,
a molecule related to serotonin (a neurotransmitter that
may be dysregulated in ASD) [70], was elevated in individ-
uals with ASD and schizophrenia. Butofenine derives from
the double-methylation of serotonin and may have hallu-
cinogenic properties [71,72]. Butofenine also correlated
with scores of hyperactivity in these individuals [70]. Al-
though the subject numbers were not high in this study,
the results are consistent with a pattern of serotonin ab-
normalities that have been observed in numerous ASD
studies [63]. Abnormalities in the serotonergic system
were also observed in a study of 33 children with autism
versus 21 healthy children, which used gas chromatog-
raphy–mass spectrometry (GC-MS) to examine urinary
levels of tryptophan (an amino acid responsible for bodily
serotonin production). This form of MS is commonly used
for metabolites in blood and urine, among other applica-
tions [73]. Urinary tryptophan was significantly lower in
children with autism than healthy controls, including those
on a restricted gluten- and casein-free diet [74]. An early
study using HPLC and mass spectrometry found that
increases in a serotonin-uptake peptide were also observed
in the urine of 67% of children diagnosed with autism
(n = 135) using DSM-III-R (DSM, third edition, Revised)
criteria when compared to healthy controls (n = 126) [75].
MS evidence supports an oxidative stress theory of
autism, another current prevalent theory [17]. Oxidative
stress refers to the generation of reactive oxygen species
which can cause cellular and tissue damage [62]. GC-
MS was used to measure urinary levels of markers for
lipid peroxidation (isoprostane F(2alpha)-VI), platelet ac-
tivation (2,3-dinor-thromboxane B(2)) and endothelium
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with autism (n = 26) versus healthy control subjects
(n = 12). Subjects with autism had higher urinary
markers for lipid peroxidation and endothelium activa-
tion. Levels of lipid peroxidation correlated with levels
of platelet and endothelium activation [76]. MS is an ef-
fective means for measuring oxidative stress markers
[62] and further mass spectrometric studies of ASD
samples can help to clarify the role that oxidative stress
may play in ASD.
Taken together, these MS analyses have supported that
oxidative stress and dysregulation of serotonin and re-
lated molecules may be present in ASD. These studies
did not however, strongly support theories involving the
introduction of exogenous substances such as heavy
metals and diet-derived opioids as causal factors in ASDs.
Based on these MS findings and additional studies, the
field has moved forward in the study of endogenous mole-
cules in ASD using MS, and specifically proteomics.
Blood sera analysis in ASDs
Blood serum is one of the most common bodily fluids
that have been studied in ASD, primarily for examining
endogenous changes. This is not always a feasible
method, due to the invasive nature of a blood draw and
the possible reluctance of children and their parents to
allow this. Taurines et al., (2010) found protein differences
in 16 subjects with ASD and ADHD (n = 9, without ADHD
n = 7; ADHD = attention deficit hyperactivity disorder) ver-
sus 16 age-matched controls. They reported three peaks
with differences, however did not aim to definitively identify
the actual proteins [77]. They have suspected that the pro-
tein may be an apolipoprotein [38]. Corbett et al., (2007)
found elevations in apolipoprotein (apo) B-100 and apo A-
IV in children with high functioning versus low-functioning
autism. These researchers also observed alterations (upreg-
ulation) in complement factor H-related protein, comple-
ment C1q and fibronectin 1 and apoB-100 in children with
autism versus matched controls [78]. These results showing
changes in apolipoproteins (responsible for cholesterol me-
tabolism and transport) are consistent with current theories
proposing that disturbances in the cholesterol system may
underlie some forms of ASD [33,79,80].
Promising mass spectrometric analyses using RP-LC-
ESI-TOF-MS or MALDI-TOF-MS (common types of
MS instruments) [77,78] of blood in subjects with ASD
have begun to emerge from the Childhood Autism Risk
from Genetics and the Environment (CHARGE) Study
being conducted at the University of California, Davis, a
large study addressing numerous susceptibility factors
for autism, and their interactions [81]. For example,
blood mercury levels were found to be unaltered relative
to controls in children 2–5 years old with autism or
ASD (with developmental delay) relative to controls [82](n = 249, n = 60, n = 143, respectively). Possible pres-
ence of polybrominated diphenyl ethers (PBDEs) in chil-
dren with autism and developmental delay were also
assessed in 100 subjects from this study using GC-MS.
No differences were observed in the plasma levels of
PBDEs in children with autism or ASDs/developmental
delay in this study [83]. This report again emphasizes
the utility of MS methods for assessing the presence of
possible environmental toxins in individuals with ASDs.
It also underscores the need to assess subjects from dif-
ferent populations and geographical regions in order to
examine the possible influence of environmental con-
taminants in the etiology of ASDs. Russo and Devito
[84] found increased plasma levels of copper during ana-
lysis of plasma from 79 individuals with autism, 52 indi-
viduals with PDD-NOS, 21 individuals with Asperger's
Syndrome using ICP-MS. Further, they investigated zinc
plasma levels and found in this case no significant alter-
ations in zinc concentrations in individuals with autism,
PPD-NOS and Asperger’s Syndrome. Zinc and B-6 ther-
apy resulted in a decrease in copper concentration in
autism and PPD-NOS patients but not in patients with
Asperger’s Syndrome whereas the zinc levels were higher
in all of the three conditions [84].
An addition application for MALDI-TOF in the study
of ASD lies in the analysis of genomic modification, such
as DNA methylation. For example, MALDI-TOF-MS
has been shown to be more suitable for high-throughput
methylation analysis in blood testing of individuals for
the fragile X syndrome than the current gold-standard
for molecular diagnosis of this disorder, Southern blot-
ting. One study showed that differential methylation of
two fragile X-related epigenetic elements within the fra-
gile X mental retardation gene intron 1 (FMR1) was re-
lated to depletion of fragile X mental retardation gene
product (FMRP) expression [85]. An additional study
examining FMR1 intron 1 methylation used MALDI-
TOF MS to analyze the blood of 74 controls compared
with 62 premutation (between 55–200 CGG repeats in
the FMR1 gene) or 18 full mutation (more than 200
CGG repeats) females. These investigators found that
FMR1 intron 1 hyper-methylation was predictive of ver-
bal cognitive impairment assessed using Wechsler intel-
ligence quotient tests [86]. This is an example of how
MS can be used to measure a biochemical parameter
that is predictive of behavior. As other ASD biomarkers
are revealed, these may also be correlated with behavior
and used to predict ASD severity. Such information
could in turn be used to guide types of treatments and
when to initiate treatment.
Salivary analysis in ASDs
Saliva has been assessed using mass spectrometry and
saliva components match the contents of blood in many
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examining protein differences in individuals with ASDs.
Saliva may provide an accessible biomaterial identifying
biomarkers, for example, elevated phosphorylated tau has
been measured in the saliva of subjects with Alzheimer’s
disease relative to controls [90] and salivary uric acid has
been used as a biomarker for metabolic syndrome [91].
However, only one published study examining saliva com-
ponents in ASDs is currently available. Castagnola and
colleagues (2006) used one type of MS (HPLC-ESI-Ion
Trap-MS or High Performance Liquid Chromatography-
ElectroSpray Ionization- Ion Trap- Mass Spectrometry)
to measure salivary peptides in individuals with ASDs
(12 with an autism diagnosis, 1 with Asperger’s Syndrome,
14 with PDD-NOS) versus age-matched controls. Phos-
phorylation levels of statherin, histatin 1 and acidic
proline-rich proteins (entire and truncated isoforms) were
significantly lower in subjects with ASDs. Lower phos-
phorylation levels of at least one peptide was found in
66% of all ASD subjects [92].
Limitations of MS
MS is a versatile tool that one can use in investigation of
bodily fluids such as sera, saliva or urine (and many
other fluids). However, when MS is used to investigate
these fluids, several factors have to be kept in mind, such
as sample preparation, sample investigation, data ana-
lysis and data interpretation. Each of these steps in
which the sample is being processed also has some limi-
tations and one should be aware of them. Perhaps one
of the greatest features of a MS-based experiment is
both an advantage and a limitation One MS experiment
can produce an enormous amount of information/data,
however, limitations of MS experiments lie within the
data analysis. Although one can obtain a high amount of
data, there is a challenge is in interpreting the results. In
the most successful MS experiments we do not know or
understand the meaning of about 30% of the spectra.
Therefore, no matter how many weaknesses one MS
instrument has (e.g. dynamic range, resolution, etc.), the
bottleneck and limitation of a MS experiment is re-
stricted to data interpretation, or bioinformatics. Due to
the large amounts of data and need for interpretation,
one may focus on one set of proteins selecting a set with
both biological and clinical relevance. Therefore, the limita-
tions of the MS-based experiments are not MS instrument-
based, but rather bioinformatics-based limitations.
Conclusions
Proteomics and investigation of possible ASD gene
products is one clear application for MS in ASDs. The
proteomic researcher using MS needs to consider how-
ever, refinements of MS techniques for protein analysis.
Simply measuring proteins levels and looking for changesare not sufficient, interpretation of data is also important,
if not the key. A proteomics experiment using MS in-
volves several steps, and these steps are continuing to be
refined by researchers. Specifically: 1) sample fraction-
ation, enzymatic digestion of proteins into peptides, 3)
analysis, 4) database search and interpretation, and 5) data
validation, typically using Western blotting (WB) [36]. For
example, our recent study found that peptides containing
a cysteine residue will be identified as alkylated, but also
other peptides. The akylation of non-cysteine-containing
peptides was not previously possible to consider in a pro-
teomic database search. This emphasizes that database
searching also is in need of refinement in order to improve
MS analysis. Therefore, we proposed that during a protein
search the researcher should have the option of searching
for any alkylated peptide at the N-terminal amino acid [59].
In addition to continued refinements of MS techniques,
proteomic studies using MS tend to focus on identifica-
tion of novel proteins [57,60,93,94] or on increases and
decreases in proteins [54,58], but there are other aspects
of protein modifications that can be studied. For example,
structural characterization, post-translational modifica-
tions or alterations in both stable and transient protein-
protein interactions may all be a subject of study
[33,36,46-48,55-57,59,62,93-97]. These changes can mod-
ify protein function and are important to consider. For
example, have recently described the combination of
Blue Native PAGE (BN-PAGE) or Colorless Native PAGE
(CN-PAGE) with MS as a powerful means for measuring
protein-protein interactions [36,48,49,52,95,97]. Additional
refinements in proteomic analysis using mass spectrometry
continue to be developed [48,53-57,93,94,96,97] and will
undoubtably increase the already formidable power of this
technique. Proteomic analysis can also be accomplished at
several levels, including supracellular, subcellular, intracellu-
lar, extracellular, peptides, proteins or protein complexes.
Proteomic analysis can focus on classical structural or func-
tional analysis and also on a specific aspect of the proteome,
such as protein oxidation, phosphoproteomics, protein
methylation or protein secretion [53,62,85,86,92,98].
Future directions
Several putative markers for ASDs have been identified
using mass spectrometry applied to various human bio-
materials. Such markers include serotonergic markers,
indications of oxidative stress, hypophosphorylation, hy-
permethylation (in the case of Fragile X) as well as apoli-
poprotein and complement protein dysregulation. Future
studies may concentrate on additional post-translational
modifications, such as protein nitrosylation, carbonylation,
eliminylation. These are modifications that occur in hu-
man conditions and because they denature a protein’s
function most of the time irreversibly they may be of
interest for study in ASD.
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ples may be reflective of multiple elements that are dis-
turbed in ASDs and may also reflect ASD heterogeneity.
This heterogeneity is also mirrored in the more than 100
genes and 40 genomic loci brought in association with
ASD. This implicates that large pools of samples are
needed in order to produce results with statistical power.
Current theories propose that ASDs have multiple sub-
types and etiologies. Future proteomic studies, including
those utilizing mass spectrometry, may therefore reveal
a biomarker signature unique to each subtype. Bio-
marker signatures may in turn aid in subtyping ASDs or
in determining that different gene mutations may result
in common protein perturbations. Correlation of mass
spectrometric protein evidence with behavioral measures
could additionally aid in defining protein biomarkers as
predictive indicators of ASD behavioral symptoms, in-
deed at least one study has confirmed this possibility
[86]. Refinements of protein analytical techniques, such
as the development of more sensitive instruments with
the ability to detect more proteins, complemented with
advanced bioinformatics software for data interpretation
will undoubtably advance the field. The availability of
new technology will make the re-analysis of biological
products in subjects with ASD versus matched controls
possible and worthwhile and with the potential to yield
additional novel results.
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